SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

Continuously expanding the scope of potential indications for SN1011 HONG KONG, June 9, 2022 – (ACN Newswire) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is […]

Angelalign Announces 2021 Annual Results

HONG KONG, Mar 25, 2022 – (ACN Newswire via SEAPRWire.com) – Angelalign Technology Inc. (“Angelalign” or “Company”; stock code 6699) was pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2021 (the “Reporting Period”) today. In 2021, the company achieved robust business growth amid the market volatility […]

Memiontec Secures its Largest Contract to date following Award of a New S$56.6 Million Contract by PUB

Singapore, Mar 25, 2022 – (ACN Newswire via SEAPRWire.com) – Memiontec Holdings Ltd. (“Memiontec” or the “Company”, and together with its subsidiaries, the “Group”), a total water solutions provider in Asia, wishes to announce that the Group has been awarded a S$56.6 million contract (the “Contract”) by the Public Utilities Board (“PUB”), Singapore’s National Water […]

IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Approved by FDA

HONG KONG, Mar 14, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, the Investigational […]

IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA

HONG KONG, Feb 17, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 11 […]

Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer’s Disease In The United States

TOKYO, Dec 21, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that, effective January 1, 2022, Biogen will reduce the wholesale acquisition cost (WAC) of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in the United States by approximately 50%. For a patient of average weight (74 kg), the yearly cost […]

Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia

TOKYO, Dec 20, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. today announced it has entered into an agreement with Gilead Sciences, Inc. for the commercialization and distribution of filgotinib (generic name, product name: Jyseleca), an oral, JAK1 preferential inhibitor for indications of rheumatoid arthritis (RA), ulcerative colitis, and Crohn’s disease in Asia […]

Gradiant Secures Five New DBOOM Projects in Indonesia and Vietnam, Appoints Managing Directors to Fuel Growth

Singapore, Dec 2, 2021 – (ACN Newswire via SEAPRWire.com) – Gradiant, a leading global cleantech water treatment solutions provider and projects developer, has announced the award of five design-build-own-operate-maintain (DBOOM) water treatment projects in Indonesia and Vietnam. Gradiant will provide end-to-end water treatment solutions through a customized approach using its proprietary suite of technologies to […]

Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension

TOKYO, Nov 11, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today results of new clinical, biomarker and safety assessments of brain amyloid reduction and five-year clinical status of people living with early Alzheimer’s disease (AD) from the lecanemab Phase 2b 201 and the open-label extension (OLE) studies. The […]

Fujitsu and Aichi Cancer Center Develop AI System to Offer Patients Personalized Cancer Treatment

TOKYO, Oct 19, 2021 – (JCN Newswire via SEAPRWire.com) – Aichi Cancer Center (1) and Fujitsu Limited today announced the development of an AI solution able to select effective medical treatment from a wide range of drugs based on patients’ individual cancer types and various genomic variants (2). Figure1. The newly developed system The effectiveness […]

Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

TOKYO, Sep 28, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. today announced that Eisai has initiated a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company’s investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early […]

Gradiant Achieves Strong Growth Across Asia in Cleantech Water Treatment during the Pandemic

– Gradiant demonstrated strong growth during the prolonged COVID-19 pandemic– Gradiant won 26 new projects in 2021 YTD across the Asia Pacific region– Contract wins are in cleantech water treatment solutions with new clients, applications, markets, and geographies, including long-term DBOOM concession agreements– Since the onset of the pandemic, Gradiant has secured 56 new projects […]

New treatment option for schizophrenia Reagila(R) listed on PBS

MELBOURNE, Sep 6, 2021 – (ACN Newswire via SEAPRWire.com) – A new treatment for schizophrenia in adults, Reagila(R) (cariprazine), was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 September, providing patients with an additional treatment option. Approved in the US since 2015 and EU since 2017, Reagila is approved in over 52 countries for […]

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)

TOKYO, Jul 30, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) — granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021 — following 18 months of treatment […]

Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

TOKYO, Jul 27, 2021 – (JCN Newswire via SEAPRWire.com) – Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer’s disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELM (aducanumab-avwa) injection 100 mg/mL solution at the Alzheimer’s Association […]

Central Global Bhd Signs MoU for JV to Build RM250M Kwasa Damansara Sewage Treatment Plant

KUALA LUMPUR, Jun 9, 2021 – (ACN Newswire via SEAPRWire.com) – Main Market-listed Central Global Berhad’s (“CGB) construction arm, Proventus Bina Sdn Bhd (“PBSB”), has signed a Memorandum of Understanding (“MoU”) to explore a proposed joint venture (“JV”) with Multi Scopes Sdn Bhd (“MSSB”) for a sewage treatment plant in Selangor. CGB executive chairman Dato’ […]

MHIEC Supplies Incinerators for First Waste-to-Energy Plant in Xiaogan, Hubei Province, China

TOKYO, Apr 27, 2021 – (JCN Newswire via SEAPRWire.com) – Mitsubishi Heavy Industries Environmental & Chemical Engineering Co., Ltd. (MHIEC), a part of Mitsubishi Heavy Industries (MHI) Group, has delivered two state-of-the-art stoker furnaces* for a large-scale waste-to-energy (WtE) plant in Xiaogan, Hubei Province, China. This facility has capacity to process approximately 1,500 tonnes of […]

Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China – First Glucokinase Activator (GKA) Globally

SHANGHAI, CHINA, Apr 23, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). Dorzagliatin is the first glucokinase activator (GKA) to submit […]

Suntrap Life Technologies Discovers Natural anti-COVID-19 Compound

Guangzhou, China, Dec 23, 2020 – (ACN Newswire) – ‘LeSoleil’, a naturally active compound, was discovered as a therapeutic candidate for use against COVID-19. As the new coronavirus began to spread globally, Suntrap Life Technologies Ltd established a special research team. The project, “Research on Anti-New Coronavirus (COVID-19) Prevention Products”, was launched in an emergency […]

NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19

SHELTON, CT / ACCESSWIRE, Sep 16, 2020 – (ACN Newswire) – NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program […]

Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China

Beijing and Shanghai, China, Aug 17, 2020 – (ACN Newswire) – Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. The agreement aims to provide Chinese diabetes patients with access to a new treatment option, building on Bayer’s […]